Stock CUBIST PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Cubist Pharmaceuticals Inc

Equities

US2296781071

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cubist Pharmaceuticals Inc
2014 Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug RE
2014 Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
BU
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
BU
Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug
RE
Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.
PR
Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback
RE
Merck : to take on superbugs with Cubist Pharma buy
RE
Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation
BU
AstraZeneca : Merck to take on superbugs with Cubist Pharma buy
RE
Apple : S&P 500 posts worst day since Oct; energy shares sink
RE
Cubist Pharmaceuticals : options unusually active before Merck deal
RE
Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT
RE
Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action
PU
Cubist Pharmaceuticals : Names Dr. Patrick Vink Chief Operating Officer
BU
Cubist Pharmaceuticals : to Present at Jefferies 2014 Healthcare Conference
BU
Cubist Pharmaceuticals : Reports Third Quarter 2014 Financial Results
BU
Cubist Pharmaceuticals : Technical Data on Biotech Equities - Intrexon, Keryx Biopharma, Spectrum Pharma, Sangamo BioSciences, and Cubist Pharma
PR
Cubist Pharmaceuticals : Names Robert J. Perez Chief Executive Officer
BU
Cubist Pharmaceuticals : to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014
BU
Cubist Pharmaceuticals : to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014
BU
Cubist Pharmaceuticals : to Present New Data on Antibiotics Portfolio at IDWeek 2014
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Cubist Pharmaceuticals Inc